By Justin Petrone

Fluidigm plans to invest $18.2 million in new financing on R&D for its gene-expression, genotyping, and sequence-capture applications, and to grow its global sales and marketing force, according to a company representative.

Spokesperson Howard High told BioArray News this week that the new funding, raised from a private placement of its stock, should also provide Fluidigm with "enough cushion to reach profitability."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.